Skip to main content

David Charles Montefiori, PhD

Professor of Surgery
Office: Surgical Oncology Res Fac, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

Dr. Montefiori is Professor and Director of the Laboratory for AIDS Vaccine Research and Development in the Department of Surgery, Division of Surgical Sciences, Duke University Medical Center. His major research interests are viral immunology and AIDS vaccine development, with a special emphasis on neutralizing antibodies. One of his highest priorities is to identify immunogens that generate broadly cross-reactive neutralizing antibodies for inclusion in HIV vaccines.  Many aspects of the neutralizing antibody response are studied in his laboratory, including mechanisms of neutralization and escape, epitope diversity among genetic subtypes and geographic origins, ontogeny of broadly neutralizing antibody responses and computationally-assisted vaccine design. Over the years he has explored multiple types of assays for neutralizing antibodies and other potential antiviral antibodies, focusing on assay optimization, standardization, validation and high throughput. The scope of research covers HIV-infected individuals and nonhuman primate models of simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection.  Dr. Montefiori also directs a large AIDS vaccine immune monitoring program, which operates in compliance with Good Clinical Laboratory Practice and has served as a national and international resource for standardized assessments of neutralizing antibody responses in preclinical and clinical trials of candidate AIDS vaccines since 1988. In 2002 he chaired the Antibody Laboratory Standardization Working Group that assisted in the design of the Global HIV Vaccine Enterprise Strategic Plan for HIV vaccines. He currently directs the Core Neutralizing Antibody Laboratories for the HIV Vaccine Clinical Trials Network (HVTN), the NIH Preclinical HIV-1 Vaccine Program and the Center for HIV/AIDS Vaccine Immunology- Immunogen Design (CHAVI-ID). He also directs a large Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) as part of the Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD). He has published over 500 original research papers that have helped shape the scientific rationale for antibody-based HIV-1 vaccines.

Education and Training

  • Ph.D., Clemson University, 1982

Selected Grants

Publications

Weissman, Drew, Mohamad-Gabriel Alameh, Thushan de Silva, Paul Collini, Hailey Hornsby, Rebecca Brown, Celia C. LaBranche, et al. “D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.” Cell Host Microbe, December 1, 2020. https://doi.org/10.1016/j.chom.2020.11.012.

Full Text

Khattar, S. K., S. Samal, C. C. LaBranche, D. C. Montefiori, P. L. Collins, and S. K. Samal. “Retraction: Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector (PLoS ONE (2013) 8:10 (e78521) DOI: 10.1371/journal.pone.0078521).” Plos One 15, no. 12 December (December 1, 2020). https://doi.org/10.1371/journal.pone.0244046.

Full Text

Musich, Thomas, Vishal Thovarai, David J. Venzon, Venkatramanan Mohanram, Iskra Tuero, Leia K. Miller-Novak, Sabrina Helmold Hait, et al. “A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques.” J Virol 94, no. 24 (November 23, 2020). https://doi.org/10.1128/JVI.01225-20.

Full Text

Schorcht, Anna, Tom L. G. M. van den Kerkhof, Christopher A. Cottrell, Joel D. Allen, Jonathan L. Torres, Anna-Janina Behrens, Edith E. Schermer, et al. “Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers.” J Virol 94, no. 24 (November 23, 2020). https://doi.org/10.1128/JVI.01214-20.

Full Text

Alam, S Munir, Kenneth Cronin, Robert Parks, Kara Anasti, Haitao Ding, Eden P. Go, Heather Desaire, et al. “Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor.” J Virol 94, no. 21 (October 14, 2020). https://doi.org/10.1128/JVI.00958-20.

Full Text

Tuyishime, Marina, Carolina Garrido, Shalini Jha, Matt Moeser, Dieter Mielke, Celia LaBranche, David Montefiori, et al. “Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.” J Clin Invest 130, no. 10 (October 1, 2020): 5157–70. https://doi.org/10.1172/JCI135557.

Full Text

Baden, Lindsey R., Daniel J. Stieh, Michal Sarnecki, Stephen R. Walsh, Georgia D. Tomaras, James G. Kublin, M Juliana McElrath, et al. “Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.” Lancet Hiv 7, no. 10 (October 2020): e688–98. https://doi.org/10.1016/S2352-3018(20)30229-0.

Full Text

Wu, Fan, Ilnour Ourmanov, Andrea Kirmaier, Sivan Leviyang, Celia LaBranche, Jinghe Huang, Sonya Whitted, Kenta Matsuda, David Montefiori, and Vanessa M. Hirsch. “SIV infection duration largely determines broadening of neutralizing antibody response in macaques.” J Clin Invest 130, no. 10 (October 1, 2020): 5413–24. https://doi.org/10.1172/JCI139123.

Full Text

Cottrell, Christopher A., Jelle van Schooten, Charles A. Bowman, Meng Yuan, David Oyen, Mia Shin, Robert Morpurgo, et al. “Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates.” Plos Pathog 16, no. 8 (August 2020): e1008753. https://doi.org/10.1371/journal.ppat.1008753.

Full Text

Antanasijevic, Aleksandar, George Ueda, Philip J. M. Brouwer, Jeffrey Copps, Deli Huang, Joel D. Allen, Christopher A. Cottrell, et al. “Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens.” Plos Pathog 16, no. 8 (August 2020): e1008665. https://doi.org/10.1371/journal.ppat.1008665.

Full Text

Pages